A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14020390
Abstract: Simple Summary KRAS is the most common oncogene in human cancers and has long been considered ‘‘undruggable’’—that is, until recently, when covalent inhibitors that selectively target KRASG12C substitution were developed. The satisfactory results of multicenter… read more here.
Keywords: inhibitor; therapy; krasg12c inhibitors; krasg12c ... See more keywords